760207-83-8

Basic information

• Product Name: 3-bromo-5-chloropyridine-2-carbonitrile
• Synonyms: 3-bromo-5-chloro-2-Pyridinecarbonitrile;3-bromo-5-chloropyridine-2-carbonitrile;3-Bromo-5-chloro-2-cyanopyridine;3-BroMo-5-chloropicolinonitrile;3-broMo-2-cyano-5-chloropyridine
• CAS NO: 760207-83-8
• Molecular Formula: C₆H₂BrClN₂
• Molecular Weight: 217.453
• Mol File: 760207-83-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 297.491°C at 760 mmHg
• Flash Point: 133.718°C
• Appearance: /
• Density: 1.854g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -4.96±0.20(Predicted)
• CAS DataBase Reference: 3-bromo-5-chloropyridine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-chloropyridine-2-carbonitrile(760207-83-8)
• EPA Substance Registry System: 3-bromo-5-chloropyridine-2-carbonitrile(760207-83-8)

Safety Data

• Hazardous Substances Data: 760207-83-8(Hazardous Substances Data)

Usage

General Description

3-bromo-5-chloropyridine-2-carbonitrile is a chemical compound with the molecular formula C6H2BrClN2. It is a substituted pyridine derivative that contains a carbonitrile functional group. 3-bromo-5-chloropyridine-2-carbonitrile is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is important to note that 3-bromo-5-chloropyridine-2-carbonitrile is classified as a hazardous substance and should be handled with care and proper safety precautions. Additionally, it is important to store and transport this compound in a tightly sealed container to prevent any potential contamination or exposure.

InChI:InChI=1/C6H2BrClN2/c7-5-1-4(8)3-10-6(5)2-9/h1,3H

Upstream product

• 137628-17-2 2,3-dibromo-5-chloro-pyridine 
• 107-12-0 propiononitrile 

Downstream Products

• 1600512-70-6 (3R)-5-amino-3-(5-((3-chloro-5-fluoro-1,7-naphthyridin-8-yl)amino)-2-fluorophenyl)-3,6-dimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1600508-37-9 (3R,6R)-5-Amino-3-(5-((3-chloro-5-fluoro-1,7-naphthyridin-8-yl)amino)-2-fluorophenyl)-6-fluoro-3,6-dimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1600508-52-8 (R)-5-amino-3-(5-((5-bromo-3-chloro-1,7-naphthyridin-8-yl)amino)-2-fluorophenyl)-3,6,6-trimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1600512-91-1 (R)-5-amino-3-(5-((3-chloro-5-vinyl-1,7-naphthyridin-8-yl)-amino)-2-fluorophenyl)-3,6,6-trimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1600512-92-2 (R)-8-((3-(5-amino-3,6,6-trimethyl-1,1-dioxido-3,6-dihydro-2H-1,4-thiazin-3-yl)-4-fluorophenyl)-amino)-3-chloro-1,7-naphthyridine-5-carbaldehyde 
• 1600508-55-1 (R)-5-amino-3-(5-((3-chloro-5-(hydroxymethyl)-1,7-naphthyridin-8-yl)-amino)-2-fluorophenyl)-3,6,6-trimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1600508-56-2 (R)-5-amino-3-(5-((3,5-dichloro-1,7-naphthyridin-8-yl)amino)-2-fluorophenyl)-3,6,6-trimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1393575-76-2 3-chloro-1,7-naphthyridin-8(7H)-one 
• 1600508-19-7 N-(3-((3S)-5-amino-3-(fluoromethyl)-6,6-dimethyl-1,1-dioxido-3,6-dihydro-2H-1,4-thiazin-3-yl)-4-fluorophenyl)-5-fluoro-3-methoxy-1,7-naphthyridin-8-amine 
• 1624604-77-8 8-((3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4,5-difluorophenyl)amino)-5-fluoro-1,7-naphthyridine-3-carbonitrile 
• 1624603-32-2 (4S,6S)-4-(5-((3-chloro-5-fluoro-1,7-naphthyridin-8-yl)amino)-2-fluorophenyl)-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine 
• 1624603-23-1 8-((3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)amino)-5-fluoro-1,7-naphthyridine-3-carbonitrile 
• 1260672-65-8 3,8-dichloro-1,7-naphthyridine 

Relevant articles and documents

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.